When Biogen and its partner Eisai announced in March that they’d halted two simultaneous Phase 3 clinical trials on an Alzheimer’s drug based on disappointing
The US Food and Drug Administration has approved esketamine to treat adults whose depression hasn’t responded to other antidepressants, the agency announced in a statement